FI118265B - Förfarande för att detektera risken för akut myokardinfarkt eller kranskärlssjukdom - Google Patents

Förfarande för att detektera risken för akut myokardinfarkt eller kranskärlssjukdom Download PDF

Info

Publication number
FI118265B
FI118265B FI20040052A FI20040052A FI118265B FI 118265 B FI118265 B FI 118265B FI 20040052 A FI20040052 A FI 20040052A FI 20040052 A FI20040052 A FI 20040052A FI 118265 B FI118265 B FI 118265B
Authority
FI
Finland
Prior art keywords
leu
ala
ser
pro
thr
Prior art date
Application number
FI20040052A
Other languages
English (en)
Finnish (fi)
Other versions
FI20040052A0 (sv
FI20040052A (sv
Inventor
Mia Pirskanen
Tomi-Pekka Tuomainen
Jukka T Salonen
Jani Haarus
Faisel Yunus
Original Assignee
Jurilab Ltd Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jurilab Ltd Oy filed Critical Jurilab Ltd Oy
Priority to FI20040052A priority Critical patent/FI118265B/sv
Publication of FI20040052A0 publication Critical patent/FI20040052A0/sv
Priority to PCT/FI2005/050007 priority patent/WO2005068653A1/en
Priority to EP05701762A priority patent/EP1711629A1/en
Priority to US10/586,312 priority patent/US20070299025A1/en
Publication of FI20040052A publication Critical patent/FI20040052A/sv
Application granted granted Critical
Publication of FI118265B publication Critical patent/FI118265B/sv

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6858—Allele-specific amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4721—Cationic antimicrobial peptides, e.g. defensins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
FI20040052A 2004-01-15 2004-01-15 Förfarande för att detektera risken för akut myokardinfarkt eller kranskärlssjukdom FI118265B (sv)

Priority Applications (4)

Application Number Priority Date Filing Date Title
FI20040052A FI118265B (sv) 2004-01-15 2004-01-15 Förfarande för att detektera risken för akut myokardinfarkt eller kranskärlssjukdom
PCT/FI2005/050007 WO2005068653A1 (en) 2004-01-15 2005-01-17 Method for detecting the risk of cardiovascular diseases such as acute myocardial infarction and coronary heart disease by analysing defensin
EP05701762A EP1711629A1 (en) 2004-01-15 2005-01-17 Method for detecting the risk of cardiovascular diseases such as acute myocardial infarction and coronary heart disease by analysing defensin
US10/586,312 US20070299025A1 (en) 2004-01-15 2005-01-17 Method for Detecting the Risk of Cardiovascular Diseases Such as Acute Myocardial Infarction and Coronary Heart Disease By Analysing Defesin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20040052 2004-01-15
FI20040052A FI118265B (sv) 2004-01-15 2004-01-15 Förfarande för att detektera risken för akut myokardinfarkt eller kranskärlssjukdom

Publications (3)

Publication Number Publication Date
FI20040052A0 FI20040052A0 (sv) 2004-01-15
FI20040052A FI20040052A (sv) 2005-07-16
FI118265B true FI118265B (sv) 2007-09-14

Family

ID=30129385

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20040052A FI118265B (sv) 2004-01-15 2004-01-15 Förfarande för att detektera risken för akut myokardinfarkt eller kranskärlssjukdom

Country Status (4)

Country Link
US (1) US20070299025A1 (sv)
EP (1) EP1711629A1 (sv)
FI (1) FI118265B (sv)
WO (1) WO2005068653A1 (sv)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2789941A1 (en) * 2009-02-26 2010-09-02 The Board Of Trustees Of The University Of Illinois Infertility associated defb-126 deletion polymorphism
CN102552306B (zh) * 2010-12-13 2015-04-08 马鞍山国声生物技术有限公司 一种减少中性粒细胞抗菌肽产量的小分子干扰rna
RU2488111C1 (ru) * 2012-05-23 2013-07-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Тверская государственная медицинская академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО Тверская ГМА Минздрава России) Способ определения риска развития инфаркта миокарда у больных с острым коронарным синдромом
CN117757914A (zh) * 2021-08-08 2024-03-26 华中科技大学同济医学院附属协和医院 Il5基因中与冠心病相关的snp位点及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002085308A2 (en) * 2001-04-24 2002-10-31 Epigenesis Pharmaceuticals, Inc. Antisense and anti-inflammatory based compositions to treat respiratory disorders
WO2003008387A1 (en) * 2001-07-20 2003-01-30 Oy Juvantia Pharma Ltd Compounds useful for treatment or prevention of disease mediated by alpha-2b-adrenoceptor
FI116940B (sv) * 2001-07-20 2006-04-13 Juvantia Pharma Ltd Oy Föreningar användbara för behandling eller förebyggande av en sjukdom medierad av alfa-2B-adrenoceptorn
FI115532B (sv) * 2002-10-07 2005-05-31 Jurilab Ltd Oy Förfarande för att upptäcka risken för kardiovaskulära sjukdomar
GB0300718D0 (en) * 2003-01-13 2003-02-12 Ares Trading Sa Proteins
EP1616194A2 (en) * 2003-04-08 2006-01-18 Genova, Ltd. Secreted polypeptide species associated with cardiovascular disorders
EP1634086A2 (en) * 2003-05-30 2006-03-15 Genova Ltd. Secreted polypeptide species associated with cardiovascular disorders

Also Published As

Publication number Publication date
WO2005068653A1 (en) 2005-07-28
FI20040052A0 (sv) 2004-01-15
EP1711629A1 (en) 2006-10-18
FI20040052A (sv) 2005-07-16
US20070299025A1 (en) 2007-12-27

Similar Documents

Publication Publication Date Title
KR101582321B1 (ko) 심장성 부정맥의 위험 관리를 위한 유전적 마커
Ek et al. Mutation analysis of peroxisome proliferator-activated receptor-γ coactivator-1 (PGC-1) and relationships of identified amino acid polymorphisms to Type II diabetes mellitus
Buraczynska et al. Renalase gene polymorphisms in patients with type 2 diabetes, hypertension and stroke
DK2471954T3 (en) Susceptibility genetic variants associated with cardiovascular diseases
Gerull et al. Identification of a novel frameshift mutation in the giant muscle filament titin in a large Australian family with dilated cardiomyopathy
JP6628226B2 (ja) 痛風発症素因の評価方法
US20090098557A1 (en) Identification of genetic markers associated with parkinson disease
Yoshida et al. Association of genetic variants with hemorrhagic stroke in Japanese individuals
EP2116618A1 (en) Diagnosis and treatment of Kawasaki disease
WO2013080227A1 (en) Genetic variants useful for risk assessment of arterial disease
WO2002098355A2 (en) Methods and reagents for diagnosis and treatment of insulin resistance and related conditions
Totomoch-Serra et al. The ADRA2A rs553668 variant is associated with type 2 diabetes and five variants were associated at nominal significance levels in a population-based case–control study from Mexico City
Kim et al. Novel in-frame deletion mutation in FLCN gene in a Korean family with recurrent primary spontaneous pneumothorax
FI118265B (sv) Förfarande för att detektera risken för akut myokardinfarkt eller kranskärlssjukdom
US20100167285A1 (en) Methods and agents for evaluating inflammatory bowel disease, and targets for treatment
Rissanen et al. New variants in the glycogen synthase gene (Gln71His, Met416Val) in patients with NIDDM from eastern Finland
US20050053956A1 (en) Detection of a predisposition for the development of coronary artery disease
M'dimegh et al. Identification of a novel AGXT gene mutation in primary hyperoxaluria after kidney transplantation failure
JP4956565B2 (ja) Ｅｄｇ５遺伝子多形ｖ２８６ａと二型糖尿病および静脈血栓症／肺塞栓症との関連性、並びに、その利用
JP2008000096A (ja) 尿路結石症の発症リスク判定方法、及び発症リスク判定用キット
US6414131B1 (en) Gene and methods for diagnosing neuropsychiatric disorders and treating such disorders
de Jong et al. No association between Annexin A5 genetic variants and deep venous thrombosis
CN101622361A (zh) 用于心律不齐的风险管理的遗传标记物
JP5119378B2 (ja) ベータアゴニストに対する気管支拡張反応の検出及び予測方法
JP2004344039A (ja) Ｃａｌｐａｉｎ（カルパイン）１０遺伝子による２型糖尿病のリスク診断方法

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 118265

Country of ref document: FI